Shares of Quotient Limited (NASDAQ:QTNT) saw unusually-strong trading volume on Wednesday . Approximately 2,920,769 shares traded hands during mid-day trading, an increase of 1,224% from the previous session’s volume of 220,625 shares.The stock last traded at $5.19 and had previously closed at $4.64.
A number of equities analysts have recently commented on QTNT shares. Zacks Investment Research lowered Quotient Limited from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 26th. ValuEngine lowered Quotient Limited from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Finally, BTIG Research reiterated a “buy” rating and issued a $12.00 price objective on shares of Quotient Limited in a research note on Thursday, August 31st.
The firm’s market cap is $74.61 million. The company has a 50-day moving average price of $4.66 and a 200-day moving average price of $5.86.
Quotient Limited (NASDAQ:QTNT) last released its quarterly earnings results on Monday, August 7th. The company reported ($0.55) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.55). The firm had revenue of $6.83 million for the quarter, compared to analysts’ expectations of $5.70 million. Quotient Limited had a negative net margin of 381.66% and a negative return on equity of 13,050.41%. Equities research analysts predict that Quotient Limited will post ($2.01) EPS for the current fiscal year.
In other Quotient Limited news, insider D J. Paul E. Cowan sold 45,540 shares of the stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $3.52, for a total value of $160,300.80. Following the transaction, the insider now directly owns 26,666 shares of the company’s stock, valued at approximately $93,864.32. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider D J. Paul E. Cowan sold 100,000 shares of the stock in a transaction dated Wednesday, October 18th. The shares were sold at an average price of $4.64, for a total transaction of $464,000.00. Following the completion of the transaction, the insider now directly owns 26,666 shares in the company, valued at $123,730.24. The disclosure for this sale can be found here. Over the last three months, insiders sold 375,197 shares of company stock worth $1,639,728. Insiders own 29.00% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in QTNT. Northern Trust Corp bought a new position in Quotient Limited in the 2nd quarter valued at about $1,783,000. State Street Corp bought a new position in Quotient Limited in the 2nd quarter valued at about $1,728,000. Scholtz & Company LLC bought a new position in Quotient Limited in the 2nd quarter valued at about $939,000. Ameriprise Financial Inc. raised its holdings in Quotient Limited by 5.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,829,895 shares of the company’s stock valued at $13,468,000 after acquiring an additional 90,057 shares during the period. Finally, Vanguard Group Inc. bought a new position in Quotient Limited in the 2nd quarter valued at about $523,000. 57.70% of the stock is currently owned by hedge funds and other institutional investors.
Quotient Limited Company Profile
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.